Neuberger Berman Group LLC Mirati Therapeutics, Inc. Transaction History

Neuberger Berman Group LLC

$123 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Nov 14, 2024	BUY	$41.99 - $62.38 $303,377 - $450,695	7,225 New	7,225 $424,000
Q4 2023 Feb 09, 2024	SELL	$41.99 - $62.38 $824,599 - $1.23 Million	-19,638 Reduced 73.1%	7,225 $424,000
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $242,499 - $395,588	8,723 Added 48.09%	26,863 $1.17 Million
Q2 2023 Aug 11, 2023	BUY	$36.13 - $49.49 $62,649 - $85,815	1,734 Added 10.57%	18,140 $655,000
Q1 2023 May 12, 2023	BUY	$36.54 - $54.26 $43,117 - $64,026	1,180 Added 7.75%	16,406 $609,000
Q4 2022 Feb 13, 2023	SELL	$41.27 - $98.62 $129,092 - $308,483	-3,128 Reduced 17.04%	15,226 $689,000
Q3 2022 Nov 15, 2022	SELL	$59.5 - $86.7 $38,913 - $56,701	-654 Reduced 3.44%	18,354 $1.28 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $68,373 - $154,887	1,746 Added 10.11%	19,008 $1.28 Million
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $5.3 Million - $10.6 Million	-69,903 Reduced 80.2%	17,262 $1.33 Million
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $11.5 Million - $16.6 Million	87,165 New	87,165 $12.3 Million
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $2.68 Million - $3.59 Million	-20,257 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$144.0 - $179.73 $372,096 - $464,422	2,584 Added 14.62%	20,257 $3.27 Million
Q1 2021 May 13, 2021	BUY	$158.92 - $221.61 $68,971 - $96,178	434 Added 2.52%	17,673 $3.03 Million
Q4 2020 Feb 10, 2021	BUY	$162.05 - $240.27 $2.79 Million - $4.14 Million	17,239 New	17,239 $3.79 Million
Q2 2019 Aug 13, 2019	SELL	$59.49 - $104.71 $356,940 - $628,260	-6,000 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$43.65 - $78.95 $261,900 - $473,700	6,000 New	6,000 $440,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.

Account